J&J takes part in a $36m round for the development of presbyopia correction eye drops
Visus Therapeutics, an American pharmaceutical company based in Seattle, announced yesterday the completion of a $36 million financing round to fund the company’s research on its Brimochol product, an eye drop drug designed to correct the effects of presbyopia with one daily application. The drug is currently in the second ...
To continue reading this article register now.
Already an Eyewear Intelligence subscriber? Sign in here.
Become a member today for full access from just €7,29 a week!
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.